Sarepta Therapeutics falls on revenue miss, weak outlook

[cafead]

via Sarepta Therapeutics (NASDAQ:SRPT) reported second quarter earnings that beat analyst expectations, but revenue fell short and the company provided weaker-than-expected guidance for fiscal year 2025, sending shares down about 11% in after-hours trading.

article source